ABSTRACT
India harbors worlds highest number of people with diabetes. Estimation of Blood Glucose, important in management of diabetes is done either in a clinical laboratory using wet chemistry kits or with SMBG device using dry-chemistry strips. To determine the possible factors affecting the results of blood glucose, a survey was undertaken in both segments. In the surveyed area, among lab participants, only 10% actually did calibration with calibrators. Half of the labs in the survey have performed IQC measures such as by using Internal Quality Control Materials (IQCM), but not with mandatory each batch of assay and among that, 20% used it on daily routine. Only 40% labs have verified the quality of standards provided with kits but none checked the manufacturers claim about its sensitivity, linearity, absorption wavelength, incubation intervals, color stability interval and the interferences. There are several studies demonstrating that diabetes can be controlled in a better way if patients have access to cost-free adequate supplies, especially of blood-glucose test strips along with a training class, consultations with dietitian and monthly support meetings. In the absence of such government-sponsored support systems for people with diabetes in India, we decided to undertake survey that would help us to understand the practices followed by the SMBG users and the level of understanding among them regarding their device and device strips. The survey brought out some important facts that would have a direct consequence on the management of diabetes. The users were not provided training about the use of the device and its strips, 55% had heard about the expiry date of the strips, but only 6% knew about Technical (desiccators) Expiry of strips. Very few (~12%) had crosschecked their results from a clinical lab and this was when 25% of the users did not believe the results they got on their device. The results are presented here.
PDF Abstract XML References Citation
How to cite this article
URL: https://scialert.net/abstract/?doi=tmr.2007.185.192
INTRODUCTION
According to the Diabetes Atlas, 2006, published by the International Diabetes Federation, the number of people with diabetes in India currently around 40.9 million is expected to rise to 69.9 million by 2025 unless urgent preventive steps are taken (Mohan et al., 2007). Diabetes is recognized as one of the most severe health problem in the world, attacking men, women, children and the elderly. It is a leading cause of kidney failure, (Anonymous, 2005), blindness in adults, nervous system damage and amputations. It has a major risk factor for heart disease, stroke and birth defects (Anonymous, 2004). SMBG device is considered an important component of preventive care in diabetes management (Clarke et al., 1987; Evans et al., 1999) and is strongly recommended to Type-1 diabetics (Anonymous, 2000, 2003). Also, if SMBG is not used properly or overused may lead to misleading results and increase in healthcare costs (Nichols et al., 2007). Two methods are available to both IDDM and NIDDM patients to monitor their blood glucose, one is by wet chemistry method in any clinical chemistry lab or by using SMBG device at home. Both methods need scrupulous adherence to quality assurance practices. Since at both the ends these practices are not mandatory in India, we wanted to find out the scenario by conducting two surveys to cover these two segments. The data is presented here.
MATERIALS AND METHODS
Two surveys were designed to understand the market trends, clinical/pathology lab practices and e ase and understanding of SMBG users about their devices (Table 1), during March 2006 to March 2007.
Survey-1
Survey on Practices Followed by Clinical Chemistry Labs
Survey-1, meant for clinical chemistry labs, was divided into three parts, (a) a feedback from the suppliers of diagnostic kits and IQC materials in the surveyed area, (b) a feedback from the quality control managers of participating labs on their analytical practices in the form of questionnaire and (c) enrollment of these labs in our External Quality Assessment Scheme (EQAS).
Survey-I
(a) Diagnostic kit dealers (Feedback on the demand of Quality Control Material)
To determine the market of internal quality control materials in Nagpur area (Vidarbha region, Maharashtra State, India), a short survey was done with five leading diagnostic dealers that cater to 95% of all operating clinical labs of the region. They were asked about their total number of clients, their sale of calibrators and control sera and its quantum (Table 2).
Table 1: | Fact file of clinical lab tests and SMBG |
![]() |
Table 2: | Feedback survey from local diagnostic dealers |
![]() |
Table 3: | The feedback from the participating clinical lab practitioners |
![]() |
(b) Clinical/Pathology Laboratory (Feedback from Quality Managers)
In the second part of Survey-1, a total of 44 request letters were sent to small-scale clinical laboratories to participate in a survey. The participating labs were asked to answer a questionnaire about their quality control practices (Table 3) and to report assayed values of requested analytes in the two unknown specimens.
(c) External Quality Assessment Program (Two Specimens)
These labs were then recruited in the third part of the survey-I. All participating labs were sent bovine-sera in ethanadiol stabilizing agent as specimens. This sera was received under the ACBI/CMC-EQAS. ACBI/CMC conducts External Quality Assurance program for all voluntarily participating clinical chemistry labs in India http://www.acbiindia.org). This sera was used as a specimen as it could be refrigerated many times and was stable at room temperature for one day http://www.cmcvellore.ac.in). As previously informed, on a given day two unknown specimens were dispatched in sterile single use container to each lab for analyzing Glucose by GOD-POD. Each specimen was carefully sealed and delivered within 1 h to city labs and within a day to outstation labs.
Survey-II: Survey of SMBG Use
Survey-II was primarily designed to survey the level of operational and extra-operational knowledge of users about SMBG device and to determine their routine practices in using them. In survey-II, a total of 250 diabetic patients using SMBG device from 6 months to 8 years participated verbally by answering 25 questions. Participants were informed about the objective of this survey and were asked questions in the language of their choice. The participants, 131 Males and 119 Females were from a cross-section of society with differing socio-economic background (Table 6).
RESULTS AND DISCUSSION
Two methods are available to both IDDM and NIDDM patients to monitor their blood glucose, one is by wet chemistry method in any clinical chemistry lab or by using SMBG device at home (Table 1).
Survey-I
The outcome of the first part of Survey I is shown in Table 4 and 5. All the five participating dealers in the survey have a clientele ranging from 120 to 400 labs with a sum of 1130 labs. Considering common clients for more than one dealer and from inputs of dealers, it was estimated that the total number of labs in the region is around 500 (Table 4 and 5).
The survey revealed that about 36 labs ask for QCM from their dealers and on taking the details of each, many names were in duplicate that brought down the actual buyers of IQCM to 16. There was one dealer who dealt in calibrators and sold it to only one buyer. Three dealers were dealing in 2 to 3 different brands of internal quality control material and selling it to all prospective buyers. Accreditation guidelines of NABL do not mention mandatory use of calibrators on routine, as long as the results of IQCM fall within acceptable range, whereas, the application of multilevel IQCM in each batch of assay is mandatory (ISO 15197). The results of the survey reveal the alarmingly low number of labs using calibrators and control.
In a questionnaire sent to participating private laboratories (Table 3), 50% labs informed performing IQC (Internal Quality Control) measures and 70% labs participated in only one EQAS (External Quality Assessment Scheme) in clinical chemistry. Among participants, 40% knew the importance of using calibrator for calibrating clinical assays but only 10% actually performed it. Half of the labs in the survey have performed IQC measures such as using internal quality control materials (IQCM), but not routinely used it along with each batch of assay, whereas, 20% participants used it daily. Moreover, only 40% labs have verified the quality of standards provided with the reagent kits but none of the participants have ever checked the manufacturers claim about its sensitivity, linearity, absorption wavelength, incubation intervals, color stability interval and the interferences. A good 80% labs acknowledged verifying all grossly abnormal values by suitable means, but only 20% of these labs checked the calibration status of their pipettes. On questioning participants whether it should be made compulsory to attend regular scientific updates, 70% said yes, but all the participants rejected the idea of compulsory involvement in internal quality control measures and participation in external quality control schemes. Moreover, none of the participants endorsed the need to have a body for regulating practices of clinical laboratories in India. All the participating labs preferred to use reference intervals for all biochemical analytes from the standard textbooks, rather than generating their own reference intervals. Among the participants the best score of a lab was 65% and the worst was Zero. In the third part of Survey I, initially only four out of 44 labs consented to the request to participate in the survey; showing their reluctance to participate in such EQAP. Similar reluctance was also observed from the fact that 1587 labs participated in CMC/ACBI-EQAS program in 2004. That number rose to 1775 in the year 2005, although there are at least 50,000 Labs operating in India (Francis, 2002).
Two specimens were sent to participating labs for glucose assay. The average difference from the mean value is 11 and 10.3 mg dL-1 for specimen 1 and 2, respectively, with a highest difference of 25.1 mg dL-1 (16.7%). The average SDs for all participating labs is 1.409 and 1.716 for specimen 1 and 2, respectively and 60% labs obtained 2SD. The 30% of the participating labs that received specimen-1 and 20% of the participating labs that received specimen-2 obtained the results between 2 and 3 SD. Ten percent participants for specimen1 and 20% participants of specimen-2 obtained results beyond 3SD.
Table 4: | Survey report on glucose (specimen-1) |
![]() |
Table 5: | Survey report on glucose (specimen-2) |
![]() |
Table 6: | Questionnaire for SMBG users practices and knowledge |
![]() |
As per accreditation norms of NABL, all results should be within 2SD for IQCM and within 3SD for EQAS. A corrective action is advised for results beyond 3SD or for results continuously beyond 2SD parameter.
The analytical evaluation study for blood glucose with 10 participant labs under the survey did not show any blunder in the results, although a few of them showed more inaccuracy than others. Survey-2: This survey brought out some glaring facts, such as:
• | Manufacturers and suppliers did not arrange training for SMBG buyers. They are only interested in the sale. |
• | Users are not interested in reading elaborate user manuals. |
• | Users have low dependability on their SMBG results. |
• | Many users are ignorant about technical expiry of strips and even after awareness, cost burden pushes them to intentionally ignore. |
• | None of the IDDM participants have ever monitored their blood glucose, 4 times a day as per ADA guidelines. |
• | The quality control solutions are not included in the SMBG kit by most of the manufacturers, moreover they are also not available off the counter and all such reasons make its users unaware about its usefulness. |
Survey-II
In India, there are many more challenges for a proper usage of SMBG devices by its users especially due to socio-economic conditions (Table 6). Moreover, all such devices marketed and available in India have their user manuals and strip literatures either in English or in other foreign languages. This is very important since only 34% population of India understands English Language, although, English is Indians second language but only after Hindi (Anonymous, 2005) and almost negligible number of people understand other foreign languages. Also, it is important to mention that these instructions are often exhaustive (one of them has 133 pages for devices), elaborate, scientific and hardly readable (with a very small font size). It is worth a mention that these non-analytical parameters are very important for an overall performance of device and its strips (Anonymous, 1990). The survey showed that although 56% of the users could read and understand English, less than a third number (29%) of participants had read the device user manual and mere 08% had read SMBG device strips user instructions. A good 90% participants accepted that prior knowledge of working of device is necessary but only 32% actually received any training by a responsible person (not compulsorily a diabetic trainer and includes SMBG-retailers). This is on the backdrop that 55% were aware of the concept of expiry and 36% agreed that they do use strips before the expiry date on the bottle, However, the most startling revelation was the lack of awareness with participants since only 06% were aware of technical (desiccators) expiry of strips, since, on making them aware of technical expiry (often within 2 to 3 months), about 34% showed willingness to use the strips within technical expiry. Some of the participants accepted to have used 50 strips in a bottle for up to one year; this is almost 4 to 6 times of permissible duration. None of the participants had any idea about the quality control solutions and its usefulness in crosschecking the results. Probably this is the reason why only 30% participants believed in their SMBG results. Among participants only 6% (IDDM or NIDDM) of them were performing tests more than 4 times a week on their SMBG as advised by ADA (Anonymous, 1995). The 94% participants did not show any willingness to buy quality control solutions even when made available at low price. The SMBG is not been used by the participants for what it is developed for, testing glucose at odd hours and at bedtime. The survey also highlighted the improper storage of strips, since only 26% participants closed the cap of the strip container immediately after taking out the strips. This also suggests fast `aging of the strips, which may further affect the sensitivity of strips (Frishman et al., 1992). We are fully aware that the cost of regular utilization of SMBG strips is a costly proposition for majority of people (Bowker et al., 2004), more so, for Indians in view of the poor economic scene. It was also found that SMBG devices are more popular in medium to higher income groups of the Indian society. But cutting across various strata of the society, none of the IDDM patients of the surveyed group acknowledged testing blood glucose at least 4 times a day and only 6% of patients (IDDM or NIDDM) acknowledged going by a plan of testing at least 4 times a week (Evan Benjamin, 2002).
CONCLUSIONS
Authors acknowledge that the sample size in this study was small and a more in depth and extended approach is needed to draw any conclusive decisions. The results obtained here may not be extrapolated to visualize a global scenario even in the Indian context, but will certainly help to visualize a situation in small towns and cities of India and other equivalently placed countries.
ABBREVIATIONS
SMBG | : | Self Monitoring Blood Glucose |
IQCM | : | Internal Quality Control Material |
EQAS | : | External Quality Assessment Scheme |
QCM | : | Quality Control Material |
ACBI/CMC | : | Association of Clinical Biochemists of India/Christian Medical College, Vellore, India |
NABL | : | National Accreditation Board for Testing and Calibrating Laboratories (India) |
ADA | : | American Diabetes Association |
REFERENCES
- Anonymous, 2003. Standards of medical care for patients with diabetes mellitus. Am. Diabetes Asso. Diabetes Care, 26: S33-50.
CrossRefPubMedDirect Link - Bowker, S.L., C.G. Mitchell and S.R. Majumdar, 2004. Lack of insurance coverage for testing supplies is associated with poorer glycemic control in patients with type-2 diabetes. CMAJ., 171: 39-43.
CrossRefDirect Link - Clarke, W.L., D. Cox, L.A. Gonder-Frederick, W. Carter and S.L. Pohl, 1987. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. Diabetes Care, 10: 622-628.
Direct Link - Evans, J.M.M., R.W. Newton and D.A. Ruta, 1999. Frequency of blood glucose monitoring in relation to glycemic control: Observational study with diabetes database. BMJ., 319: 83-86.
Direct Link - Evan, M.B., 2002. Self-monitoring of blood glucose: Basics. Clin. Diabetes, 20: 45-47.
CrossRefDirect Link - Mohan, V., S. Sandeep, R. Deepa, B. Shah and C. Varghese, 2007. Epidemiology of type 2 diabetes: Indian scenario. Indian J. Med. Res., 125: 217-230.
PubMedDirect Link - Nichols, J.H., R.H. Christenson, W. Clarke, A. Gronowski and C.A. Hammett-Stabler et al., 2007. Executive summary. The National Academy of Clinical Biochemistry Laboratory Medicine practice guideline: Evidence-based practice for point-of-care testing. Clin. Chim. Acta, 379: 14-28.
PubMedDirect Link